A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure

Journal of the American College of Cardiology

Volumn 55, Issue 18, 2010, Pages 1907-1914

  Gao, Runlin ^a   Zhang, Jian ^a   Cheng, Liuquan ^b   Wu, Xuesi ^c   Dong, Wei ^b   Yang, Xinchun ^d   Li, Tianchang ^e   Liu, Xifu ^f   Xu, Yabei ^f   Li, Xinyan ^f   Zhou, Mingdong ^f  

^a FUWAI HOSPITAL   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f Zensun Science and Technology Co Ltd   (China)

Author keywords

Cardiac remodeling; Chronic heart failure; Magnetic resonance imaging; Recombinant human neuregulin 1; rhNRG 1

Indexed keywords

NEU DIFFERENTIATION FACTOR; PLACEBO; RECOMBINANT HUMAN NEUREGULIN 1; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CHEST TIGHTNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ELECTROCARDIOGRAM; ENDDIASTOLIC VOLUME; ENDSYSTOLIC VOLUME; EXCITEMENT; FATIGUE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HEART VOLUME; HUMAN; HYPERHIDROSIS; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY;

ADULT; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUREGULIN-1; RECOMBINANT PROTEINS; STROKE VOLUME; VENTRICULAR REMODELING;

EID: 77952317892     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.044     Document Type: Article

References (14)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146.
2. Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007;190:1-65.
3. Rohrbach S, Niemann B, Silber RE, Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and attenuated activation. Basic Res Cardiol 2005;100:240-9.
4. Lemmens K, Doggen K, Keulenaer GW. Neuregulin-1 and its potential role in the control of cardiac function. Heart Fail Monit 2008;5:119-24.
5. Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM, Zuppinger C. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp Cell Res 2007;313:1588-601.
6. Lemmens K, Segers VF, Demolder M, De Keulenaer GW. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte crosstalk. J Biol Chem 2006;281:19469-77.
7. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-15.
8. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998;273:10261-9.
9. Zhou MD. Cardiac muscle function and manipulation. PCT application no. PCT/AU99/01137, December 21, 1999. Published as WO00/37095, June 29, 2009.
10. Baliga RR, Pimental DR, Zhao YY, et al. NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEKMAPK-RSK. Am J Physiol 1999;277:H2026-37.
11. Liu X, Gu X, Li Z, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006;48:1438-47.
12. Chan JY, Takeda M, Briggs LE, et al. Identification of cardiac-specific myosin light chain kinase. Circ Res 2008;102:571-80.
13. Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009;138:257-70.
14. Lemmens K, Fransen P, Sys SU, et al. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 2004;109:324-6.